Literature DB >> 9177242

Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy.

T Koschinsky1, C J He, T Mitsuhashi, R Bucala, C Liu, C Buenting, K Heitmann, H Vlassara.   

Abstract

Endogenous advanced glycation endproducts (AGEs) include chemically crosslinking species (glycotoxins) that contribute to the vascular and renal complications of diabetes mellitus (DM). Renal excretion of the catabolic products of endogenous AGEs is impaired in patients with diabetic or nondiabetic kidney disease (KD). The aim of this study was to examine the oral absorption and renal clearance kinetics of food AGEs in DM with KD and whether circulating diet-derived AGEs contain active glycotoxins. Thirty-eight diabetics (DM) with or without KD and five healthy subjects (NL) received a single meal of egg white (56 g protein), cooked with (AGE-diet) or without fructose (100 g) (CL-diet). Serum and urine samples, collected for 48 hr, were monitored for AGE immunoreactivity by ELISA and for AGE-specific crosslinking reactivity, based on complex formation with 125I-labeled fibronectin. The AGE-diet, but not the CL-diet, produced distinct elevations in serum AGE levels in direct proportion to amount ingested (r = 0.8, P < 0.05): the area under the curve for serum ( approximately 10% of ingested AGE) correlated directly with severity of KD; renal excretion of dietary AGE, although normally incomplete (only approximately 30% of amount absorbed), in DM it correlated inversely with degree of albuminuria, and directly with creatinine clearance (r = 0.8, P < 0.05), reduced to <5% in DM with renal failure. Post-AGE-meal serum exhibited increased AGE-crosslinking activity (two times above baseline serum AGE, three times above negative control), which was inhibited by aminoguanidine. In conclusion, (i) the renal excretion of orally absorbed AGEs is markedly suppressed in diabetic nephropathy patients, (ii) daily influx of dietary AGEs includes glycotoxins that may constitute an added chronic risk for renal-vascular injury in DM, and (iii) dietary restriction of AGE food intake may greatly reduce the burden of AGEs in diabetic patients and possibly improve prognosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9177242      PMCID: PMC21074          DOI: 10.1073/pnas.94.12.6474

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Renal fate of circulating advanced glycated end products (AGE): evidence for reabsorption and catabolism of AGE-peptides by renal proximal tubular cells.

Authors:  A Gugliucci; M Bendayan
Journal:  Diabetologia       Date:  1996-02       Impact factor: 10.122

2.  Nutritional consequences of the Maillard reaction. Amino acid availability from fructose-leucine and fructose-tryptophan in the rat.

Authors:  V C Sgarbieri; J Amaya; M Tanaka; C O Chichester
Journal:  J Nutr       Date:  1973-05       Impact factor: 4.798

Review 3.  Pathogenic effects of advanced glycosylation: biochemical, biologic, and clinical implications for diabetes and aging.

Authors:  H Vlassara; R Bucala; L Striker
Journal:  Lab Invest       Date:  1994-02       Impact factor: 5.662

4.  Mechanism of autoxidative glycosylation: identification of glyoxal and arabinose as intermediates in the autoxidative modification of proteins by glucose.

Authors:  K J Wells-Knecht; D V Zyzak; J E Litchfield; S R Thorpe; J W Baynes
Journal:  Biochemistry       Date:  1995-03-21       Impact factor: 3.162

5.  Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats.

Authors:  H Vlassara; L J Striker; S Teichberg; H Fuh; Y M Li; M Steffes
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-22       Impact factor: 11.205

6.  Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits.

Authors:  H Vlassara; H Fuh; T Donnelly; M Cybulsky
Journal:  Mol Med       Date:  1995-05       Impact factor: 6.354

7.  Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency.

Authors:  R Bucala; Z Makita; G Vega; S Grundy; T Koschinsky; A Cerami; H Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-27       Impact factor: 11.205

8.  Reactive glycosylation endproducts in diabetic uraemia and treatment of renal failure.

Authors:  Z Makita; R Bucala; E J Rayfield; E A Friedman; A M Kaufman; S M Korbet; R H Barth; J A Winston; H Fuh; K R Manogue
Journal:  Lancet       Date:  1994-06-18       Impact factor: 79.321

9.  Identification of the major site of apolipoprotein B modification by advanced glycosylation end products blocking uptake by the low density lipoprotein receptor.

Authors:  R Bucala; R Mitchell; K Arnold; T Innerarity; H Vlassara; A Cerami
Journal:  J Biol Chem       Date:  1995-05-05       Impact factor: 5.157

10.  Antibacterial activity of lysozyme and lactoferrin is inhibited by binding of advanced glycation-modified proteins to a conserved motif.

Authors:  Y M Li; A X Tan; H Vlassara
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

View more
  184 in total

Review 1.  [Non-enzymatic glycation and oxidative stress in chronic illnesses and diabetes mellitus].

Authors:  P P Nawroth; A Bierhaus; G E Vogel; M A Hofmann; M Zumbach; P Wahl; R Ziegler
Journal:  Med Klin (Munich)       Date:  1999-01-15

Review 2.  Advanced glycation: an important pathological event in diabetic and age related ocular disease.

Authors:  A W Stitt
Journal:  Br J Ophthalmol       Date:  2001-06       Impact factor: 4.638

Review 3.  Glycoxidation and diabetic complications: modern lessons and a warning?

Authors:  Helen Vlassara; Jaime Uribarri
Journal:  Rev Endocr Metab Disord       Date:  2004-08       Impact factor: 6.514

4.  Advanced glycation endproduct (AGE) receptor 1 is a negative regulator of the inflammatory response to AGE in mesangial cells.

Authors:  Changyong Lu; John Cijiang He; Weijing Cai; Huixian Liu; Li Zhu; Helen Vlassara
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-02       Impact factor: 11.205

Review 5.  Does accumulation of advanced glycation end products contribute to the aging phenotype?

Authors:  Richard D Semba; Emily J Nicklett; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2010-05-17       Impact factor: 6.053

6.  Depletion of reactive advanced glycation endproducts from diabetic uremic sera using a lysozyme-linked matrix.

Authors:  T Mitsuhashi; Y M Li; S Fishbane; H Vlassara
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

7.  Paradox of circulating advanced glycation end product concentrations in patients with congestive heart failure and after heart transplantation.

Authors:  A Heidland; K Sebeková; A Frangiosa; L S De Santo; M Cirillo; F Rossi; M Cotrufo; A Perna; A Klassen; R Schinzel; N G De Santo
Journal:  Heart       Date:  2004-11       Impact factor: 5.994

Review 8.  Mechanistic targeting of advanced glycation end-products in age-related diseases.

Authors:  Sheldon Rowan; Eloy Bejarano; Allen Taylor
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-08-29       Impact factor: 5.187

9.  Identifying advanced glycation end products as a major source of oxidants in aging: implications for the management and/or prevention of reduced renal function in elderly persons.

Authors:  Helen Vlassara; Jaime Uribarri; Luigi Ferrucci; Weijing Cai; Massimo Torreggiani; James B Post; Feng Zheng; Gary E Striker
Journal:  Semin Nephrol       Date:  2009-11       Impact factor: 5.299

10.  In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs.

Authors:  Angela Cassese; Iolanda Esposito; Francesca Fiory; Alessia P M Barbagallo; Flora Paturzo; Paola Mirra; Luca Ulianich; Ferdinando Giacco; Claudia Iadicicco; Angela Lombardi; Francesco Oriente; Emmanuel Van Obberghen; Francesco Beguinot; Pietro Formisano; Claudia Miele
Journal:  J Biol Chem       Date:  2008-10-27       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.